{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:22:41Z","timestamp":1788153761152,"version":"build-2803163510"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"\n Objective<\/jats:title>\n This retrospective study evaluated the impact of p53-abnormal (p53abn) status on recurrence patterns and outcomes among patients with non-invasive, high-grade endometrial cancer (EC) treated at the Brazilian National Cancer Institute (INCA) between 2010 and 2025.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Eligible patients had high-grade histologies\u2014including endometrioid grade 3 (ECG3), serous (USC), clear cell (CC), carcinosarcoma (CS), mixed, or undifferentiated tumors\u2014without myometrial invasion. Clinical, surgical, and pathological characteristics, as well as recurrence and survival data, were reviewed. Immunohistochemical analysis of p53 expression was performed, and p53 status was correlated with clinical outcomes, particularly recurrence rate.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Fifty-nine patients met the inclusion criteria, with a mean age of 65 years. Most underwent total hysterectomy with or without bilateral salpingo-oophorectomy (59.3%); 40.7% also received lymphadenectomy or omentectomy. Histologic distribution was mainly endometrioid (39.0%) and serous (39.0%). Forty-six (78%) and 13 (22%) had p53 abnormal and normal tumors. Seven patients (11.9%) received chemotherapy and 15 (25.4%) received radiotherapy. Three patients had already disease outside uterus. Among 56 patients with FIGO stage IC disease, recurrence occurred in 16.1%, predominantly at extra-pelvic sites (33.3% abdominal, 22.2% distant). Five-year recurrence was 23.2% for p53abn tumors versus 0% for wild-type, and 12.5% of patients died\u2014mostly within the p53abn subgroup.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The findings suggest that even in non-invasive high-grade EC, p53 abnormalities confer higher recurrence risk and poorer outcomes, while wild-type tumors show excellent prognosis. These results support individualized treatment approaches and highlight the need for larger, prospective validation studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/pore.2026.1612543","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:10:10Z","timestamp":1788153010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of p53 status on recurrence patterns and oncologic outcomes in non-invasive high-grade endometrial cancer"],"prefix":"10.3389","volume":"32","author":[{"given":"Eduardo","family":"Paulino","sequence":"first","affiliation":[{"name":"Division of Clinical Research and Technological Development, Brazilian National Cancer Institute","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Branco","sequence":"additional","affiliation":[{"name":"Division of Clinical Research and Technological Development, Brazilian National Cancer Institute","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Gomes de Mesquita","sequence":"additional","affiliation":[{"name":"Division of Clinical Research and Technological Development, Brazilian National Cancer Institute","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Cristina de Melo","sequence":"additional","affiliation":[{"name":"Division of Clinical Research and Technological Development, Brazilian National Cancer Institute","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","unstructured":"Cancer today\n \n \n 2026"},{"key":"B2","volume-title":"WHO Classification of Tumours","year":"2026"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"B5","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology\n \n \n 2026"},{"key":"B6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/modpathol.3800271","article-title":"Minimal uterine serous carcinoma: a clinicopathological study of 40 cases","volume":"18","author":"Hui","year":"2005","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/IGC.0000000000000838","article-title":"Extrauterine spread, adjuvant treatment, and prognosis in noninvasive uterine papillary serous carcinoma of the endometrium","volume":"27","author":"Boyraz","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/ijgc-2023-004281","article-title":"Serous endometrial intra-epithelial carcinoma: an observational study","volume":"33","author":"Slaager","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101971","DOI":"10.1016\/j.ijgc.2025.101971","article-title":"Endometrial carcinosarcoma without myoinvasion","volume":"35","author":"Cucinella","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.3802\/jgo.2017.28.e49","article-title":"Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish gynecologic oncology group study","volume":"28","author":"Sar\u0131","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/ijgc-2023-005149","article-title":"Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion","volume":"34","author":"Jamieson","year":"2024","journal-title":"Int J Gynecol Cancer"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:10:12Z","timestamp":1788153012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":12,"alternative-id":["10.3389\/pore.2026.1612543"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612543","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1612543"}}